RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING 05/15/2025 RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME 04/16/2025 RECORDATI RARE DISEASES TO PRESENT NEW DATA IN CUSHING’S DISEASE AND CUSHING’S SYNDROME AT ENDO 2024 05/16/2024 Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next › Last page Last »
RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING 05/15/2025
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME 04/16/2025
RECORDATI RARE DISEASES TO PRESENT NEW DATA IN CUSHING’S DISEASE AND CUSHING’S SYNDROME AT ENDO 2024 05/16/2024
